Skip to main content
← All verified funding
Tier AUS

Translational Efforts to Advance Gene-based Therapies for Ultra-Rare Neurological and Neuromuscular Disorders (U01 - Clinical Trial Optional)

National Institutes of Health

Sign in and complete your Funding Passport to see whether you qualify — a transparent, rule-based verdict, not a black box.

Sign In

About this opportunity

The Ultra-Rare Gene-Based Therapy (URGenT) network supports Investigational New Drug (IND)-enabling studies and planning activities for First-in-Human (FIH) clinical testing of gene-based or transcript-directed therapeutics, such as oligonucleotides and viral-based gene therapies, for ultra-rare neurological or neuromuscular disorders. The goal of this announcement is to accelerate the development of a promising clinical candidate with robust biological rationale and demonstrated proof of concept (POC) data for the intended approach in a model system relevant to a specified patient population towards an IND filing and the initiation of a clinical trial.

Required documents

The official source lists no specific documents here — confirm requirements before applying.

Source & verification trail

First retrieved
November 20, 2026
Last verified
November 20, 2026
Content fingerprint
c5331377760e3a46…